PubMed Health⌕ Search

Biomedical subjects

V I Fomichev

Publications and source records attributed to V I Fomichev.

At least 19 recordsLinked to original sources
PubMed1995

[Use of bonnecor in the treatment of ventricular arrhythmia].

The effectiveness of the new antiarrhythmic drug bonnecor was tried in 59 patients with ventricular arrhythmia. High antiarrhythmic activity of the drug was recorded in the course doses 150 to 250 mg/day. Bonnecor effect is dose-dependent: the number of ventricular extrasystoles reduced by 75% in 62 and 74% of the patients receiving 150 mg/day and 20 mg/day, respectively. The highest effect was achieved in high-grade ventricular extrasystole. Side effects were occasional: headache lasting 1-2 hours 40-50 min after bonnecor administration, slow atrioventricular conduction (2 cases), sleep disorders (2 cases).

Adult↗
PubMed1994

[Ticlopidine].

Explore the source record for details and available documents.

Animals↗
PubMed1993

[The neurohumoral systems of patients with ischemic heart disease and under emotional-pain stress: the means for their pharmacological regulation].

The sympathetic-adrenal and kallikrein-kinin systems were studied in 225 patients with various coronary heart diseases before and after therapy with lipoic acid (150 mg/day), tocopherol (100 mg/day), anaprilin (40 mg/day), prodectin (750 mg/day) or their combination. Myocardial and adrenal catecholamine levels were measured in experiments on animals exposed to emotional pain stress. Their levels were found to be affected by lipoic acid, tocopherol, obsidan or their combinations in the same doses, taking into account species specificity. Lipoic acid therapy for patients with coronary heart disease decreased epinephrine excretion, enhanced the elimination of vanillylmandelic acid and norepinephrine. Tocopherol lowered daily urinary epinephrine levels and increased the release of vanillylmandelic acid, without changing epinephrine excretion. Emotional pain stress resulted in myocardial epinephrine accumulation and adrenal norepinephrine in the animals. Lipoic acid prevented this accumulation, whereas tocopherol did not possess this effect.

Adolescent↗
PubMed1993

[The pharmacodynamics of the new anti-arrhythmia preparation bonnecor based on the data from an acute drug test].

The pharmacodynamics of the new antiarrhythmic agent bonnecor was studied in 33 patients with coronary heart diseases and ventricular arrhythmias in the acute drug test. The parenteral formulation of the drug (0.04-0.8 mg/kg) and its tablets were given to 23 and 27 patients, respectively. Bonnecor was found to be effective in suppressing ventricular premature contractions. Its intravenous and oral efficacy is 65 and 70%), respectively. During intravenous injection, the drug showed its antiarrhythmic effect on an average of 14 minutes later, lasting about 68 minutes. During oral administration, the action of the drug started 0.5 hour later and lasted 7.2 hours. Adverse reactions were rare. An echocardiographic study revealed its negative inotropic effect which is likely to be insignificant since there was no development or increase of heart failure in any of the examinees (including 8 patients with signs of Stage I-IIA circulatory insufficiency).

Adult↗
PubMed1991

[The effect of plasmasorption on the content of natural antibodies to thrombin and alpha 2-macroglobulin in stenocardia patients].

A study was made of changes in the content of natural antibodies (N-AB) to thrombin and alpha 2-macroglobulin in patients with angina pectoris under the influence of plasma perfusion. The content of N-AB being increased, plasma perfusion makes it possible to reduce their content to normal. Provided the content of N-AB is initially normal, plasma perfusion does not produce any changes in their level. In 78% of the patients, a beneficial clinical effect was attained, being more pronounced in initially high content of N-AB.

Adult↗